TABLE 3

Association with hyperglycemia, type 2 diabetes, and dyslipidemia in the DESIR population at the end of the study and over the 9-year follow-up

n (frequency in each genotypic group)
TTMinor allele frequency (%)Overall risk at the end of the study*
nCCCTIncidence risk over the 9-year follow-up
Hyperglycemia status
    Normoglycemia2,883856 (0.30)1,444 (0.50)583 (0.20)45.27
    End-of-study cases948338 (0.36)449 (0.47)161 (0.17)40.664 × 10−5, 0.79 (0.70–0.88)
    Incident cases516187 (0.36)238 (0.46)91 (0.18)40.705×10−3, 0.83 (0.74–0.95)
Type 2 diabetes status
    Normoglycemia3,3971,048 (0.31)1,680 (0.49)669 (0.20)44.42
    End-of-study cases306103 (0.34)153 (0.50)50 (0.16)41.340.01, 0.79 (0.65–0.95)
    Incident cases18767 (0.36)88 (0.47)32 (0.17)40.640.2, 0.87 (0.71–1.08)
Dyslipidemia status
    Normolipidemia2,731898 (0.33)1,319 (0.48)514 (0.19)42.97
    End-of-study cases2,102611 (0.29)1,057 (0.50)434 (0.21)45.790.01, 1.12 (1.02–1.22)
    Incident cases959293 (0.31)472 (0.49)194 (0.20)44.840.9, 0.99 (0.91–1.09)
  • Overall risk data are P, OR (95% CI) and incident risk data are P, HR (95% CI). Hyperglycemia and type 2 diabetes were defined according to 1997 American Diabetes Association criteria and dyslipidemia according to World Health Organization criteria. Hyperglycemia was defined as impaired fasting glucose or type 2 diabetes.

  • *

    * OR from logistic regression models adjusted for age, sex, and BMI.

  • HR from Cox proportional hazards models adjusted for age, sex, and BMI.